Bravecto 1400mg may be available in the countries listed below. THERAPEUTIC CLASSIFICATION: Antiparasitic Fluralaner is an inhibitor of the arthropod nervous system.

One adult treated dog suffered a seizure during the course of the study (46 days after the second treatment). Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Every effort has been made to ensure the accuracy of the BRAVECTO 1400 mg information published above. Available for Android and iOS devices. The mode of action of fluralaner is the antagonism of the ligand-gated chloride channels (gamma-aminobutyric acid (GABA) -receptor and glutamate-receptor). Kills fleas and ticks. Each tube is packaged individually in a pouch. One treated animal experienced vomiting eight hours after administration.There were no clinically-relevant, treatment-related effects on the body weights, food consumption, reproductive performance, semen analysis, litter data, gross necropsy (adult dogs) or histopathology findings (adult dogs and puppies). Seizures have been reported in dogs receivin… The most frequently reported adverse reaction in dogs in the BRAVECTO and active control groups was vomiting.In a well-controlled laboratory dose confirmation study, one dog developed edema and hyperemia of the upper lips within one hour of receiving BRAVECTO. Select one or more newsletters to continue. 1 Chew. A comprehensive plan, based on regional risk assessment is recommended to determine an appropriate dosing interval.This product should not be given to dogs with known or suspected allergy or intolerance to fluralaner or other components of this product.BRAVECTO has not been shown to be effective for 12-weeks duration in puppies less than 6 months of age.Not for human use. This class has been associated with neurological adverse reactions including tremors, ataxia, and seizures.
Select one or more newsletters to continue. The bioavailability of fluralaner following topical administration is approximately 25%.Fluralaner has a systemic mode of action and belongs to the class of isoxazoline-substituted benzamide derivatives. One treated animal experienced loose feces with blood three hours after treatment. Ingredient matches for Bravecto 1400mg Fluralaner. Dogs with signs of flea allergy dermatitis showed improvement in erythema, alopecia, papules, scales, crusts, and excoriation as a direct result of eliminating flea infestations.There were no clinically-relevant, treatment-related effects on the body weights, food consumption, reproductive performance, semen analysis, litter data, gross necropsy (adult dogs) or histopathology findings (adult dogs and puppies). This class has been associated with neurological adverse reactions including tremors, ataxia, and seizures.

Quantifiable drug concentrations can be measured (lower than necessary for effectiveness) through 112 days. Due to climate variations across the country, Canada has highly variable distributions and abundance of flea and tick infestations. Two (2) dogs treated with BRAVECTO with no prior history of seizures each experienced a seizure. One dog with a history of seizures had a seizure the day after the second dose of the active control.In two well-controlled laboratory dose confirmation studies, one dog developed mild to moderate redness, flaking, crusts/scabs and alopecia at the treatment site from Day 1 through 14 after application of BRAVECTO on Day 0, and one dog developed self-limiting generalized erythema (possible allergic reaction) one day after treatment with BRAVECTO.In a European field study conducted in 474 cats receiving topical fluralaner, there were three reports of facial dermatitis in humans after close contact with the application site within 4 days of application.
BRAVECTO has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. One dog had two seizures a day apart about 18 days after its first dose. Association with the treatment was not substantiated in two cases and in the third case, close contact occurred before the skin at the application site was dry. The edema improved progressively through the day and had resolved without medical intervention by the next morning.Peak fluralaner concentrations are achieved between 2 hours and 3 days following oral administration and the elimination half-life ranges between 9.3 to 16.2 days. A third dog treated with BRAVECTO topical solution was observed by the owner to be off balance for about 30 minutes five days after its first dose and had no similar observations after the second dose.

BRAVECTO ® (fluralaner) Chews >88-123 lb. Product may be supplied in 1 or 2 tubes per carton. Abnormal salivation was observed on 17 occasions: in six treated dogs (11 occasions) after dosing and four control dogs (6 occasions).The following abnormalities were noted in 7 pups from 2 of the 10 dams in only the treated group during gross necropsy examination: limb deformity (4 pups), enlarged heart (2 pups), enlarged spleen (3 pups), and cleft palate (2 pups). In some countries, this medicine may only be approved for veterinary use. The cap should be rotated clockwise or counter clockwise one full turn.The cap is designed to stay on the tube for dosing.The tube is open and ready for application when a breaking of the seal is felt.Place the tube tip vertically against the skin between the shoulder blades of the dog.Avoid applying an excessive amount of solution in any one spot which may cause some solution to run or drip off of the dog.Bathing or water immersion 3 days or more after administration will not reduce the effectiveness of BRAVECTO (see Treatment with BRAVECTO may begin at any time of the year. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.We comply with the HONcode standard for trustworthy health information - Keep out of the reach of children. In order to prevent children from getting direct access to the product, keep tube(s) in unopened pouch until use. Product may be packaged in 1, 2, or 4 tablets per package.Intervet Canada Corp., subsidiary of Merck & Co., Inc., 16750, route Transcanadienne, Kirkland, QC H9H 4M7Copyright © 2020 Animalytix LLC.